Quest Diagnostics (NYSE:DGX) SVP Sells 2,628 Shares

NodeGuardian · 2026-03-07T04:26:54+00:00

Karthik Kuppusamy of Quest Diagnostics sold 2,628 shares, reducing his stake by 16.35%, despite strong earnings and a $1.0 billion buyback. Analysts rate the stock as a "Moderate Buy" with a target of $210.29.

NodeGuardian

2026-03-07 04:26:54

Abstract generation in progress

Karthik Kuppusamy, SVP at Quest Diagnostics (NYSE:DGX), sold 2,628 shares of the company’s stock on March 4th for over $538,000, reducing his stake by 16.35%. This transaction comes as Quest Diagnostics recently reported strong quarterly earnings, beating analyst estimates, and announced a $1.0 billion share buyback program and an increased quarterly dividend. Analysts currently rate the stock as a “Moderate Buy” with a consensus price target of $210.29.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.